BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26161903)

  • 1. Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues.
    Li X; Patterson JT; Sarkar M; Pedzisa L; Kodadek T; Roush WR; Rader C
    Bioconjug Chem; 2015 Nov; 26(11):2243-8. PubMed ID: 26161903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.
    Dimasi N; Fleming R; Zhong H; Bezabeh B; Kinneer K; Christie RJ; Fazenbaker C; Wu H; Gao C
    Mol Pharm; 2017 May; 14(5):1501-1516. PubMed ID: 28245132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Simple and Efficient Method to Generate Dual Site-Specific Conjugation ADCs with Cysteine Residue and an Unnatural Amino Acid.
    Zhang L; Wang Z; Wang Z; Luo F; Guan M; Xu M; Li Y; Zhang Y; Wang Z; Wang W
    Bioconjug Chem; 2021 Jun; 32(6):1094-1104. PubMed ID: 34013721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and Validation of Linkers for Site-Specific Preparation of Antibody-Drug Conjugates Carrying Multiple Drug Copies Per Cysteine Conjugation Site.
    Kumar A; Mao S; Dimasi N; Gao C
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the Development of Site-Specific Antibody-Drug Conjugation.
    Zhou Q; Kim J
    Anticancer Agents Med Chem; 2015; 15(7):828-36. PubMed ID: 25731178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ethynylphosphonamidates for the Rapid and Cysteine-Selective Generation of Efficacious Antibody-Drug Conjugates.
    Kasper MA; Stengl A; Ochtrop P; Gerlach M; Stoschek T; Schumacher D; Helma J; Penkert M; Krause E; Leonhardt H; Hackenberger CPR
    Angew Chem Int Ed Engl; 2019 Aug; 58(34):11631-11636. PubMed ID: 31250955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Site-Specific Conjugation of Thiol-Reactive Cytotoxic Agents to Nonnative Cysteines of Engineered Monoclonal Antibodies.
    Dickgiesser S; Kellner R; Kolmar H; Rasche N
    Methods Mol Biol; 2019; 2033():1-14. PubMed ID: 31332743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
    Yamada K; Ito Y
    Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.
    Thompson P; Fleming R; Bezabeh B; Huang F; Mao S; Chen C; Harper J; Zhong H; Gao X; Yu XQ; Hinrichs MJ; Reed M; Kamal A; Strout P; Cho S; Woods R; Hollingsworth RE; Dixit R; Wu H; Gao C; Dimasi N
    J Control Release; 2016 Aug; 236():100-16. PubMed ID: 27327768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orthogonal Cysteine Protection Enables Homogeneous Multi-Drug Antibody-Drug Conjugates.
    Levengood MR; Zhang X; Hunter JH; Emmerton KK; Miyamoto JB; Lewis TS; Senter PD
    Angew Chem Int Ed Engl; 2017 Jan; 56(3):733-737. PubMed ID: 27966822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homogeneous antibody-drug conjugates: DAR 2 anti-HER2 obtained by conjugation on isolated light chain followed by mAb assembly.
    Farràs M; Miret J; Camps M; Román R; Martínez Ó; Pujol X; Erb S; Ehkirch A; Cianferani S; Casablancas A; Cairó JJ
    MAbs; 2020; 12(1):1702262. PubMed ID: 31876436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer.
    White JB; Fleming R; Masterson L; Ruddle BT; Zhong H; Fazenbaker C; Strout P; Rosenthal K; Reed M; Muniz-Medina V; Howard P; Dixit R; Wu H; Hinrichs MJ; Gao C; Dimasi N
    MAbs; 2019 Apr; 11(3):500-515. PubMed ID: 30835621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Conjugation Site and Technique on the Stability and Pharmacokinetics of Antibody-Drug Conjugates.
    Kaempffe A; Dickgiesser S; Rasche N; Paoletti A; Bertotti E; De Salve I; Sirtori FR; Kellner R; Könning D; Hecht S; Anderl J; Kolmar H; Schröter C
    J Pharm Sci; 2021 Dec; 110(12):3776-3785. PubMed ID: 34363839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers.
    Ohri R; Bhakta S; Fourie-O'Donohue A; Dela Cruz-Chuh J; Tsai SP; Cook R; Wei B; Ng C; Wong AW; Bos AB; Farahi F; Bhakta J; Pillow TH; Raab H; Vandlen R; Polakis P; Liu Y; Erickson H; Junutula JR; Kozak KR
    Bioconjug Chem; 2018 Feb; 29(2):473-485. PubMed ID: 29425028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of Selenocysteine for Site-Specific Antibody Conjugation.
    Li X; Rader C
    Methods Mol Biol; 2017; 1575():145-164. PubMed ID: 28255878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proof of site-specificity of antibody-drug conjugates produced by chemical conjugation technology: AJICAP first generation.
    Matsuda Y; Malinao MC; Robles V; Song J; Yamada K; Mendelsohn BA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Mar; 1140():121981. PubMed ID: 32036254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability.
    Sussman D; Westendorf L; Meyer DW; Leiske CI; Anderson M; Okeley NM; Alley SC; Lyon R; Sanderson RJ; Carter PJ; Benjamin DR
    Protein Eng Des Sel; 2018 Feb; 31(2):47-54. PubMed ID: 29370435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conjugation site analysis of antibody-drug-conjugates (ADCs) by signature ion fingerprinting and normalized area quantitation approach using nano-liquid chromatography coupled to high resolution mass spectrometry.
    Sang H; Lu G; Liu Y; Hu Q; Xing W; Cui D; Zhou F; Zhang J; Hao H; Wang G; Ye H
    Anal Chim Acta; 2017 Feb; 955():67-78. PubMed ID: 28088282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stable and Potent Selenomab-Drug Conjugates.
    Li X; Nelson CG; Nair RR; Hazlehurst L; Moroni T; Martinez-Acedo P; Nanna AR; Hymel D; Burke TR; Rader C
    Cell Chem Biol; 2017 Apr; 24(4):433-442.e6. PubMed ID: 28330604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.